Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

Recruiting now · Not applicable

Conditions studied: Solid Tumor, Adult

In brief

ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.

Key facts

Study ID

NCT05223608

Run by

Centre Oscar Lambret

People needed

651

Starts

2022-03-03

Expected to finish

2028-03-01

Last updated by the study team

2026-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
• In neo-adjuvant, adjuvant, recurrence or metastatic situation
• Suffering from solid tumor histologically documented
• Signed written informed consent
• Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.

You may not qualify if…

• Pregnant or breastfeeding women
• Patient already treated by immunotherapy by immune checkpoint inhibitor
• Person under guardianship
• Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)

Where it is running

• Centre Oscar Lambret — Lille, Hauts-de-France, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.